19.04.2017 curasan AG  DE0005494538

DGAP-News: curasan enters into Exclusive Distribution Partnership with China-Based Fosun Group


 
DGAP-News: curasan AG / Key word(s): Contract curasan enters into Exclusive Distribution Partnership with China-Based Fosun Group 19.04.2017 / 09:06 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- - Partnership with China's leading dental manufacturer - Official launch of CERASORB(R) in May - Portfolio expansion and new permits planned for China Kleinostheim, April 19, 2017 - curasan AG (ISIN DE0005494538), a leading specialist in orthobiological medical devices, has signed an exclusive distribution agreement with Shanghai Foshion Medical Systems Co., Ltd., (Foshion Medical). Foshion Medical is one of the most important distributors in the Chinese dental market and a subsidiary of Shanghai Fosun Pharmaceutical Group Co., Ltd., a company listed on the Shanghai Stock Exchange and a leading enterprise in the Chinese health care industry. Today's agreement will give Foshion Medical the exclusive right to distribute the granular variant of the bone regeneration substance CERASORB(R), a product which has already received approval for the Chinese dental market. "In such an important market like China, Foshion Medical is the ideal partner for us," said curasan AG CEO Michael Schlenk with confidence. "Their distribution network is perfectly positioned for the Chinese market and they boast an excellent reputation among our target groups. Foshion Medical is also a strategic partner which can help coordinate our efforts to receive product approvals from the Chinese authorities." Foshion Medical will also support the planned approval of other curasan dental product variants in China, such as foam and paste. The agreement guarantees Foshion Medical the exclusive distribution rights to the entire dental product portfolio in China. "Our company has grown at an incredible rate in recent years," said Foshion Medical general manager Zhang Huizhen, explaining the company's decision to partner with curasan AG. "One of the reasons we've enjoyed such dynamic growth is that we hold our partners to very high standards, and we only work with the best, most technologically advanced products. We are already working successfully with several German companies, and we concluded that curasan AG's bone regeneration substances would be a perfect addition to our product line." A concrete marketing program has already been developed to ensure rapid entry into the market. On-site workshops and training sessions in China are already planned for May and will be lead by renowned opinion leaders from Germany. The first order is contractually scheduled for May 2017. curasan anticipates a clear sales and revenue contribution for the current 2017 fiscal year resulting from the new distribution agreement, which will be offset by expected market entry costs. The company expects to see positive earnings from the partnership starting in 2018. About curasan AG: curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in the Research Triangle Park area, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange. About Foshion Medical: Belonging to Shanghai Fosun-Pharma Group, Shanghai Foshion Medical System Co., Ltd. acts as professional agency of imported high-end dental material, instrument and equipment. Foshion Medical office is located downtown Shanghai and was founded in 2000, which today is a leading dental supply distributor in China. Foshion Medical distributes products of international partners from Germany, other European countries and USA. All products meet the highest quality requirement which can cope with the increasing requirements by dentists and dental technicians to offer better dental treatment. Owning domestic top-ranking training center and based on high beginning of dental product sales with unique service, Foshion Medical has become very influential dental agent brand nationwide. Having a most passionate love for dental business and making remarkable progress, Foshion Medical will spare no efforts to import world brands to benefit China dentistry. Contact: Ingo Middelmenne Head of Investor Relations Tel. +49 6027 40900-45 Fax +49 6027 40900-39 ingo.middelmenne@curasan.de Andrea Weidner Head of Corporate Communications Tel. +49 6027 40900-51 Fax +49 6027 40900-39 andrea.weidner@curasan.de www.curasan.de --------------------------------------------------------------------------- 19.04.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: curasan AG Lindigstraße 4 63801 Kleinostheim Germany Phone: 06027/40 900 0 Fax: 06027/40 900 29 E-mail: info@curasan.de Internet: www.curasan.de ISIN: DE0005494538 WKN: 549453 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 565457 19.04.2017


Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 3,23 5,82 5,76 5,97 6,93 6,80 5,84 6,40
EBITDA1,2 -2,97 -1,64 -1,12 2,13 -2,14 -2,22 -3,84 -3,00
EBITDA-Marge3 -91,95 -28,18 -19,44 35,68 -30,88 -32,65 -65,75 -46,88
EBIT1,4 -3,32 -2,14 -1,83 1,33 -2,66 -2,84 -4,78 -2,80
EBIT-Marge5 -102,79 -36,77 -31,77 22,28 -38,38 -41,76 -81,85 -43,75
Jahresüberschuss1 -3,47 -2,14 -1,83 1,33 -2,09 -4,00 -5,38 -2,50
Netto-Marge6 -107,43 -36,77 -31,77 22,28 -30,16 -58,82 -92,12 -39,06
Cashflow1,7 -2,72 -1,85 -0,37 2,15 -2,11 -2,55 -4,34 0,00
Ergebnis je Aktie8 -1,53 -0,90 -0,72 0.45 -0,63 -0,99 -0,99 -0,33
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Hinrik J. Schröder

INVESTOR-INFORMATIONEN
©boersengefluester.de
Curasan
WKN Kurs in € Einschätzung Börsenwert in Mio. €
549453 0,470 Verkaufen 4,26
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 15,55 0,000 0,00
KBV KCV KUV EV/EBITDA
0,57 - 0,73 -1,204
Dividende '18 in € Dividende '19e in € Div.-Rendite '18
in %
Hauptversammlung
0,00 0,00 0,00 26.06.2019
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
23.05.2019 22.08.2019 21.11.2019 13.05.2019
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
14,63% -17,54% -7,84% -48,91%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu curasan AG  ISIN: DE0005494538 können Sie bei DGAP abrufen

Gesundheit , 549453 , CUR , XETR:CUR